second-line - Globe Thesis

Keyword [second-line] Result: 101 - 120 \| Page: 6 of 7
101.	A Clinical Study Of PD-1 Antibody Combined With Anlotinib In The Second-line Or Above Treatment Of Advanced Non-small Cell Lung Cancer
102.	Effects On Anlotinib Plus Chemotherapy As Second-line Therapy In Small Cell Lung Cancer
103.	Clinical Efficacy And Safety Of Apatinib Combined With Chemotherapy In The Second-line Treatment Of Small Cell Lung Cancer
104.	The Efficacy And Safety Of Irinotecan In Combination With Anlotinib In The Second-line Treatment Of Small Cell Lung Cancer
105.	Clinical Analysis Of Second-line Treatment Of Chronic Myeloid Leukemia With Nilotinib And Dasatinib
106.	Clinical Efficacy Observation Of First-line And Second-line Treatment With Nilotinib In Chronic Myeloid Leukemia
107.	Efficacy Of Bevacizumab Combined With Chemotherapy As First-line And Second-line Treatment In Advanced Non-squamous Non-small Cell Lung Cancer
108.	Real-world Retrospective Study Of Second-line Treatment With Ratitrexed Regimen In Advanced Colorectal Cancer
109.	Efficacy And Safety Of Immunotherapy Versus Chemotherapy As Second-line Treatment On Esophageal Squamous Cell Carcinoma:Meta Analysis
110.	Efficacy And Safety Of PD-1/PD-L1 Inhibitors Versus Chemotherapy In Second-line Treatment Of Advanced Esophageal Cancer:A Meta-Analysis Of Randomized Controlled Trials
111.	Clinical Efficacy Of Icotinib In Patients Of Advanced Non-Squamous Non-Small Cell Lung Cancer Failed With The Second-Line Chemotherapy Along With Unknown EGFR Mutation
112.	Efficacy And Safety Of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy As Second-Line Treatment For Advanced Esophageal Cancer:A Meta-Analysis
113.	Efficacy And Safety Analysis Of Immune Checkpoint Inhibitors Combined With Chemotherapy And Chemotherapy Alone In Second-line Treatment Of Patients With Advanced Biliary Malignancy
114.	A Prospective Clinical Study Evaluating The Efficacy And Safety Of Combination Therapy Of Anlotinib Hydrochloride And Irinotecan In The Second-line Treatment Of Patients With Advanced Esophageal Squamous Cell Carcinoma
115.	Clinical Efficacy And Safety Of Apatinib Mesylate In Second-line Treatment Of Advanced Cholangiocarcinoma
116.	Phase Ⅱ Study Of Anlotinib Plus Sintilimab As Second-line Treatment For Patients With Advanced Biliary Tract Cancers
117.	Observation Of Clinical Efficacy Of Toripalimab Based Combination Therapy As Second-line In Esophageal Squamous Cell Carcinoma
118.	Comparisons Of Efficacy And Safety Of Different Second-line Treatments For Trastuzumab-resistant Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
119.	The Optimal Second-Line Systemic Treatment Model For Recurrent And/or Metastatic Head And Neck Squamous Cell Carcinoma:a Bayesian Network Meta-Analysis
120.	Second-line Treatment And Pathogenesis Of Primary Biliary Cholangitis And Overlapp Syndrome
<<First <Prev Next> Last>> Jump to